Patrick M. Reagan

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma”.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

New England Journal of Medicine(2017)10.1056/nejmoa1707447

N/A

1.3DataRank · unranked

5812 citations

Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson +41 more

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Journal of Clinical Oncology(2020)10.1200/jco.19.02104

N/A

0.997DataRank · unranked

767 citations

Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin +23 more

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102959

N/A

0.465DataRank · unranked

9 citations

Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen +13 more

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

Blood Advances(2023)10.1182/bloodadvances.2023011489

N/A

0DataRank · unranked

26 citations

Miriam T. Jacobs, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin +21 more

PD-1Hi CAR-T cells provide superior protection against solid tumors

Frontiers in Immunology(2023)10.3389/fimmu.2023.1187850

N/A

0DataRank · unranked

13 citations

Yeonsun Hong, Ankit Dahal, Allison T. Ryan, Sana Mir, Scott A. Gerber +3 more

S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL

Hematological Oncology(2023)10.1002/hon.3166_ot22

N/A

0DataRank · unranked

1 citations

Patrick M. Reagan, H. Li, Hayder Saeed, Riha Vaidya, Joseph M. Unger +5 more

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Journal of Clinical Oncology(2024)10.1200/jco.23.02786

N/A

0DataRank · unranked

74 citations

Jay Y. Spiegel, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin +27 more

ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors

Nature Immunology(2023)10.1038/s41590-023-01498-x

N/A

0DataRank · unranked

47 citations

Brandon L. Walling, Hye-Ran Kim, William S. Serratelli, John Lozada, Cooper J. Sailer +17 more